Summary & Overview
HCPCS J1447: Injection, tbo-filgrastim, 1 microgram
HCPCS Level II code J1447 identifies tbo-filgrastim, a granulocyte colony-stimulating factor, dosed per microgram for injection. This code is used to bill the supply of the biologic when administered to reduce the duration of neutropenia or support hematopoietic recovery. Nationally, biologic supportive therapies such as tbo-filgrastim are important for oncology care pathways and post-transplant management given their role in reducing infection risk and supporting chemotherapy delivery.
Key payers discussed include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of how J1447 is defined, the clinical context for its use, and what to expect in claims for outpatient injectable biologic services. Content covers national benchmarks where available, payer coverage considerations, and recent policy updates relevant to injectable hematopoietic growth factors. The publication also outlines coding considerations and common billing practices for service lines that deliver injectable biologics in ambulatory and hospital outpatient settings.
Data not available in the input for specific reimbursement rates, associated taxonomies, and ICD-10 linkage; those fields are noted as unavailable where applicable.
Billing Code Overview
HCPCS Level II code J1447 describes injection, tbo-filgrastim, 1 microgram. This code represents a biologic hematopoietic growth factor formulation administered as an injection. The service type is drug administration / injectable biologic. The typical site of service is outpatient infusion or injection settings, including physician offices, ambulatory infusion centers, and hospital outpatient departments.
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A typical patient is a 58-year-old female receiving chemotherapy for non-Hodgkin lymphoma who develops chemotherapy-induced neutropenia. The oncology clinic prescribes J1447 (tbo-filgrastim) to reduce duration of neutropenia and risk of febrile neutropenia. The clinical workflow: patient presents to outpatient oncology infusion center for cancer treatment or post-chemotherapy follow-up; baseline vitals and recent absolute neutrophil count (ANC) are reviewed; provider orders subcutaneous J1447 at a weight-based or fixed dose per protocol; nursing verifies allergies, prepares and documents the injection, administers subcutaneously (often in the abdomen or thigh), observes briefly for immediate reactions, and documents lot number and expiration in the medication administration record. Billing uses J1447 per microgram with the number of units corresponding to total micrograms administered; appropriate modifier(s) are appended for payer requirements and service circumstances. Typical site of service is an outpatient infusion center, oncology clinic, or ambulatory surgical center when given in conjunction with other procedures; it can also be administered in an inpatient hospital setting when clinically indicated.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
00 |